CARE Series - Controlled Substance Prescription, Harm Reduction, and Diversion



Date & Location
Monday, July 8, 2024, 12:00 PM - Thursday, July 8, 2027, 1:00 PM

Credits
AMA PRA Category 1 Credits™ (1.25 hours), ANCC Nursing Contact Hours (1.25 hours), CME-Designated Participation Credit (1.25 hours)

Overview

Review of:

  • Harm Reduction: Overview
    o What is harm reduction?
    o What is the underlying foundation of harm reduction?
    o Examples of harm reduction interventions
  • Controlled Substance Prescription and the interface with Harm Reduction: A Balancing Act
  • Attempting to save lives of drug users vs. harm that can be associated with some of these interventions
  • Prescribing controlled substances from a harm reduction orientation: what makes the most sense?
  • Diversion
    o Risk of Diversion
    o Preventing Diversion: Red flags to regulators
    o Review of reporting obligations related to diversion
  • Harm Reduction Approaches: Pros and Cons
    o Fentanyl test strips
    o Naloxone overdose reversal and advent of new compounds: xylazine, nitazenes
    o Sterile syringe distribution

Presenter

Elinore F. McCance-Katz, MD, PhD
Assistant Secretary for Mental Health and Substance Use 2017-2021
U.S. Department of Health and Human Services

Presenter Biography

Elinore McCance-Katz, M.D., Ph.D. served as the first Assistant Secretary for Mental Health and Substance Use and led the Substance Abuse and Mental Health Services Administration (SAMHSA) in the U.S. Department of Health and Human Services from 2017-2021.

She obtained her Ph.D. from Yale University with a specialty in Infectious Disease Epidemiology and is a graduate of the University of Connecticut School of Medicine. She is board certified in General Psychiatry and in Addiction Psychiatry. She is a Distinguished Fellow of the American Academy of Addiction Psychiatry with more than 30 years as a clinician, teacher, and clinical researcher.

Most recently in 2023 she served as the Medical Director of the Providence Veterans Administration Health System Opioid Treatment Program. She served as Chief Medical Officer for the Rhode Island Department of Behavioral Healthcare, Developmental Disabilities and Hospitals and as the Chief Medical Officer for the Eleanor Slater Hospital system which is Rhode Island’s state resource for patients with the most serious mental illnesses and medical illnesses requiring long term, inpatient care from 2015-17 and again from 2021-2022. Dr. McCance-Katz has spent much of her career in academic medicine. Currently she holds an appointment as Clinical Professor of Psychiatry and Human Behavior at Brown University. Previously, she served as the first Chief Medical Officer for SAMHSA. Prior to coming to SAMHSA, she served at the University of California, San Francisco as a Professor of Psychiatry, as the Medical Director for the California Department of Alcohol and Drug Programs, and as the Medical Director of SAMHSA’s Clinical Support Systems for Buprenorphine (PCSS-B) and Opioids (PCSS-O). Dr. McCance-Katz has published extensively in the areas of clinical pharmacology, medications development for substance use disorders, drug-drug interactions, and treatment of HIV infection in drug users. She served on the World Health Organization (WHO) committee that developed guidelines on the treatment of drug users living with HIV/AIDS and she served as a physician in the PEPFAR (President’s Emergency Program for AIDS Relief) initiative where she worked in Vietnam to assist in establishing methadone treatment programs to address opioid use disorder (OUD) and HIV infection in that country.


Learning Objectives
At the conclusion of this learning activity, participants will be able to:

  1. List three examples of harm reduction interventions.
  2. Identify one signal of prescribed controlled substance diversion risk.
  3. Explain pros and cons of sterile syringe distribution.

Accreditation

In support of improving patient care, Dartmouth Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

American Medical Association (AMA)
Dartmouth Health designates this Enduring Material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

American Nurses Credentialing Center (ANCC)
Dartmouth Health designates this Enduring Material for a maximum of 1.25 ANCC contact hours.

All other learners may claim CME-designated participation credit. Consult your professional licensing board regarding the applicability and acceptance of CME-designated participation credit for programs certified for credit by organizations accredited by Joint Accreditation for Interprofessional Education.

Registration/Requirements for Successful Completion
You may claim credit for successful completion of this online course. In order to claim credit, you must follow these steps:

  1. Click the Register tab above. If you are not logged into your account, you will need to log in. Use the Forgot Your Password? button if you need to reset your password.
  2. Register for the activity.
  3. Click the Content/Tests tab and then View Content to view the recording. View the entire presentation.
  4. Complete the Post-Test (attestation - return to the Content/Tests tab to find it).
  5. Click the Complete Evaluation button, or click My Account in the menu bar; then click Evaluations.
  6. Complete and Submit the Evaluation.

Bibliographic Sources

Provider Contact Information
Provider contact information for questions regarding accreditation of the activity:

Center for Learning and Professional Development
CE Office
Dartmouth Health
[email protected]